60 Degrees Pharmaceuticals (SXTP) News Today $0.19 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 7:18 AM | americanbankingnews.com60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Sees Large Growth in Short InterestJuly 25 at 8:16 PM | finanznachrichten.deSixty Degrees Pharmaceuticals: 60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA Supply Chain Upgrade SupportJuly 25 at 8:16 PM | finance.yahoo.com60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade SupportJuly 20, 2024 | msn.comDow Tumbles Over 100 Points; American Express Earnings Beat ViewsJuly 20, 2024 | finance.yahoo.com(XS2531438351.SG)July 20, 2024 | markets.businessinsider.com60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis StudyJuly 20, 2024 | msn.comWhy Are 60 Degrees Pharmaceuticals Shares Up By 50% Today?July 19, 2024 | globenewswire.com60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis StudyJuly 19, 2024 | investorplace.comWhy Is 60 Degrees (SXTP) Stock Up 56% Today?July 9, 2024 | globenewswire.com60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior TreatmentJune 27, 2024 | globenewswire.comFirst Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its KindMay 30, 2024 | globenewswire.comEnrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its KindMay 20, 2024 | globenewswire.com60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine StudyMay 16, 2024 | markets.businessinsider.comBalancing Act: Hold Rating Amid Positive Earnings and Upcoming Babesiosis Trial UncertaintiesMay 15, 2024 | globenewswire.com60 Degrees Pharmaceuticals Announces First Quarter 2024 ResultsMay 8, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious DiseasesMay 8, 2024 | globenewswire.com60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious DiseasesMay 2, 2024 | globenewswire.com60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes RequiredApril 18, 2024 | msn.com60 Degrees Pharmaceuticals (SXTP) Price Target Increased by 8.33% to 1.33April 3, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine BabesiosisApril 3, 2024 | globenewswire.com60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine BabesiosisMarch 14, 2024 | globenewswire.com60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024February 20, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida aurisFebruary 20, 2024 | globenewswire.com60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida aurisFebruary 8, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial OfficerJanuary 31, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public OfferingJanuary 31, 2024 | finance.yahoo.comWallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public OfferingJanuary 30, 2024 | marketwatch.com60 Degrees Shares Plumb New Lows After Public OfferingJanuary 30, 2024 | morningstar.com60 Degrees Pharmaceuticals IncJanuary 30, 2024 | finance.yahoo.comWallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public OfferingJanuary 30, 2024 | markets.businessinsider.comWhy Is 60 Degrees (SXTP) Stock Down 33% Today?January 30, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public OfferingJanuary 22, 2024 | msn.com60 Degrees Pharmaceuticals files to sell 4.79M unitsJanuary 22, 2024 | msn.comWhy Is 60 Degrees Pharmaceuticals Stock Trading Higher Today?January 22, 2024 | marketwatch.com60 Degrees Pharma Shares Rise 18% After Type C Meeting With FDAJanuary 22, 2024 | finance.yahoo.com60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA MeetingJanuary 16, 2024 | finance.yahoo.com60 Degrees Pharma Regains Compliance with Nasdaq Listing RequirementsDecember 28, 2023 | marketwatch.com60 Degrees Pharmaceuticals Shares Surge 28% on Approved Study of Tafenoquine as Potential Bbesiosis TreatmentDecember 26, 2023 | msn.comWhy Is Infection Treatment Focused-60 Degrees Pharmaceuticals Stock Soaring Today?December 26, 2023 | finance.yahoo.com60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024November 15, 2023 | msn.com60 Degrees to meet with FDA over developing Arakoda for babesiosisNovember 15, 2023 | sg.finance.yahoo.com60 Degrees Pharmaceuticals, Inc. (SXTP)November 15, 2023 | finance.yahoo.com60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne DiseaseOctober 20, 2023 | markets.businessinsider.comHold Rating Recommended for 60 Degrees Pharmaceuticals due to Uncertain Profitability and Strategic ShiftOctober 19, 2023 | finance.yahoo.com60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in BostonOctober 12, 2023 | finance.yahoo.com60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne DiseasesOctober 12, 2023 | marketbeat.comTrading was temporarily halted for "SXTP" at 04:10 PM with a stated reason of "News pending."September 20, 2023 | barrons.com60 Degrees Pharmaceuticals Inc.September 20, 2023 | msn.comWhy Is Infectious Disease Focused 60 Degrees Pharmaceuticals Stock Trading Lower Today?September 18, 2023 | reuters.com60 Degrees Pharma withdraws mid-stage study application for COVID drug Get 60 Degrees Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter. Email Address AI’s “Dot Com” moment (Ad)Why Nvidia could soon collapse by 50% or more (it’s happened twice before). You must watch this new exposé now! SXTP Media Mentions By Week SXTP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SXTP News Sentiment▼0.410.65▲Average Medical News Sentiment SXTP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SXTP Articles This Week▼71▲SXTP Articles Average Week Get 60 Degrees Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AEZS News Today AGRX News Today PIRS News Today MBRX News Today ABVC News Today ELAB News Today CYCN News Today MTEM News Today PPBT News Today KA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SXTP) was last updated on 7/28/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredNvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this secto...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 60 Degrees Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.